000280916 001__ 280916
000280916 005__ 20250921001952.0
000280916 0247_ $$2doi$$a10.1038/s41590-025-02230-7
000280916 0247_ $$2pmid$$apmid:40826276
000280916 0247_ $$2ISSN$$a1529-2908
000280916 0247_ $$2ISSN$$a1529-2916
000280916 0247_ $$2altmetric$$aaltmetric:180392630
000280916 037__ $$aDZNE-2025-00999
000280916 041__ $$aEnglish
000280916 082__ $$a610
000280916 1001_ $$00000-0002-8627-7056$$aWeber, Alexander N R$$b0
000280916 245__ $$aThe expanding role of the NLRP3 inflammasome from periodic fevers to therapeutic targets.
000280916 260__ $$aLondon$$bSpringer Nature Limited$$c2025
000280916 3367_ $$2DRIVER$$aarticle
000280916 3367_ $$2DataCite$$aOutput Types/Journal article
000280916 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1758101434_31853$$xReview Article
000280916 3367_ $$2BibTeX$$aARTICLE
000280916 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000280916 3367_ $$00$$2EndNote$$aJournal Article
000280916 520__ $$aUnderstanding and treating inflammation has proven a formidable challenge. The initiator and central motor of inflammation, the protein NLRP3, is an innate immune sentinel and nonspecific sensor of cellular perturbation. A wide array of inflammatory triggers prompts the formation of an NLRP3 'inflammasome' complex, leading to inflammatory interleukin-1 family cytokine release and pyroptotic cell death. Since gain-of-function mutations in NLRP3 were demonstrated to cause a rare autoinflammatory disease termed cryopyrin-associated periodic syndrome, NLRP3 has emerged as key mediator of inflammation in mouse models for many common diseases, including atherosclerosis, Alzheimer's disease and gout. But even though small-molecule NLRP3 modulators have entered clinical development, many aspects of NLRP3 activation and regulation in humans remain relatively unclear. This Review summarizes the current understanding of the molecular mechanisms that drive NLRP3 inflammasome activation and regulation, and discusses emerging targeting strategies. Understanding these processes can guide precision medicine approaches aimed at mitigating NLRP3-driven pathologies.
000280916 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x0
000280916 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000280916 650_7 $$2NLM Chemicals$$aNLR Family, Pyrin Domain-Containing 3 Protein
000280916 650_7 $$2NLM Chemicals$$aInflammasomes
000280916 650_7 $$2NLM Chemicals$$aNLRP3 protein, human
000280916 650_2 $$2MeSH$$aNLR Family, Pyrin Domain-Containing 3 Protein: metabolism
000280916 650_2 $$2MeSH$$aNLR Family, Pyrin Domain-Containing 3 Protein: genetics
000280916 650_2 $$2MeSH$$aNLR Family, Pyrin Domain-Containing 3 Protein: immunology
000280916 650_2 $$2MeSH$$aHumans
000280916 650_2 $$2MeSH$$aInflammasomes: metabolism
000280916 650_2 $$2MeSH$$aInflammasomes: immunology
000280916 650_2 $$2MeSH$$aAnimals
000280916 650_2 $$2MeSH$$aCryopyrin-Associated Periodic Syndromes: immunology
000280916 650_2 $$2MeSH$$aCryopyrin-Associated Periodic Syndromes: drug therapy
000280916 650_2 $$2MeSH$$aCryopyrin-Associated Periodic Syndromes: genetics
000280916 650_2 $$2MeSH$$aMice
000280916 650_2 $$2MeSH$$aInflammation: immunology
000280916 7001_ $$0P:(DE-2719)2811671$$aMcManus, Róisín M$$b1
000280916 7001_ $$00000-0002-4150-194X$$aHornung, Veit$$b2
000280916 7001_ $$00000-0002-7718-5002$$aGeyer, Matthias$$b3
000280916 7001_ $$aKuemmerle-Deschner, Jasmin B$$b4
000280916 7001_ $$0P:(DE-2719)2000062$$aLatz, Eicke$$b5$$udzne
000280916 773__ $$0PERI:(DE-600)2026412-4$$a10.1038/s41590-025-02230-7$$gVol. 26, no. 9, p. 1453 - 1466$$n9$$p1453 - 1466$$tNature immunology$$v26$$x1529-2908$$y2025
000280916 8564_ $$uhttps://pub.dzne.de/record/280916/files/DZNE-2025-00999_Restricted.pdf
000280916 8564_ $$uhttps://pub.dzne.de/record/280916/files/DZNE-2025-00999_Restricted.pdf?subformat=pdfa$$xpdfa
000280916 909CO $$ooai:pub.dzne.de:280916$$pVDB
000280916 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811671$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000280916 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2000062$$aExternal Institute$$b5$$kExtern
000280916 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x0
000280916 9141_ $$y2025
000280916 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2024-12-13$$wger
000280916 915__ $$0StatID:(DE-HGF)3003$$2StatID$$aDEAL Nature$$d2024-12-13$$wger
000280916 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNAT IMMUNOL : 2022$$d2024-12-13
000280916 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-13
000280916 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-13
000280916 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-13
000280916 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-13
000280916 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-13
000280916 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-13
000280916 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-13
000280916 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-13
000280916 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-13
000280916 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-13
000280916 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-13
000280916 915__ $$0StatID:(DE-HGF)9930$$2StatID$$aIF >= 30$$bNAT IMMUNOL : 2022$$d2024-12-13
000280916 9201_ $$0I:(DE-2719)1013042$$kAG McManus$$lTranslational Neuroimmunology$$x0
000280916 980__ $$ajournal
000280916 980__ $$aVDB
000280916 980__ $$aI:(DE-2719)1013042
000280916 980__ $$aUNRESTRICTED